Guggenheim has assumed coverage of Nanobiotix S.A. (NASDAQ:NBTX) with a Buy rating and a $64 price target on September 15, putting the company’s Johnson & Johnson-partnered JNJ-1900 at the center of its investment thesis.
The analyst’s attention is particularly focused on NANORAY-312, the pivotal Phase 3 study evaluating JNJ-1900 in patients with locally advanced head and neck cancer who are ineligible for platinum-based chemotherapy, with final Phase 3 data expected in the first half of 2027.
DON’T MISS: Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?
Based on its recent key opinion leader checks and analysis of the study, Guggenheim believes the trial has high odds of success. That remains the firm’s assessment rather than an established probability, but it makes the 2027 readout the most important catalyst highlighted in Guggenheim’s thesis.
Bull Case
The J&J partnership gives Nanobiotix’s lead program considerably more weight than it would have as a wholly independent development effort. Nanobiotix entered into a global licensing agreement with Johnson & Johnson (NYSE:JNJ) in 2023 for JNJ-1900, formerly known as NBTXR3.
The investigational candidate is designed as a potential first-in-class radioenhancer and is being studied across solid tumors treated with radiotherapy. J&J now serves as the global sponsor of the pivotal NANORAY-312 Phase 3 trial, and the study is evaluating radiotherapy-activated JNJ-1900 in patients with locally advanced head and neck cancer who are ineligible for platinum-based chemotherapy.
DON’T MISS: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
The Phase 3 program also underwent an important change this year. In May, J&J received FDA clearance for a protocol amendment to NANORAY-312 that eliminated the previously planned interim analysis and moved the study to an earlier final analysis requiring fewer events. Nanobiotix said there were no changes to the study’s primary and secondary endpoints, hazard ratios, or expected effect size. The company now anticipates Phase 3 data in the first half of 2027. That readout is central to Guggenheim’s bullish thesis, as following its KOL checks and study analysis, the firm characterized the pivotal study as having high odds of success.
Bear Case
The same Phase 3 study that provides Nanobiotix S.A. with a major potential catalyst also concentrates considerable clinical risk around the 2027 readout. JNJ-1900 remains investigational, and Guggenheim’s assessment that NANORAY-312 has high odds of success is an analyst view and not a clinical outcome, as the trial still has to produce its final results.
Investors should also be careful with the headline value of the J&J agreement. The approximately $2.6 billion represents potential deal value rather than money Nanobiotix has already received, and significant portions depend on future development, regulatory, and sales milestones.
The broader JNJ-1900 opportunity also remains under clinical development. Beyond NANORAY-312, J&J is evaluating the candidate in other settings, including a Phase 1b program in platinum-eligible head and neck cancer and a Phase 2 program in stage 3 unresectable non-small cell lung cancer. These programs could eventually broaden the opportunity for JNJ-1900, but their existence should not be treated as evidence of future approvals or commercial success.
Conclusion
Guggenheim’s $64 price target and Buy rating ultimately put considerable emphasis on JNJ-1900 and the approaching NANORAY-312 readout.
There are tangible reasons the program has attracted attention, which include J&J taking global sponsorship of the pivotal study and covering nearly all of its remaining costs, as well as having a broader development program underway around JNJ-1900. Guggenheim, meanwhile, sees high odds of success based on its own KOL checks and study analysis.
But that last point remains an analyst judgment, and for Nanobiotix S.A. investors, the pivotal evidence still lies ahead. With final Phase 3 data expected in the first half of 2027, NANORAY-312 represents both the clearest catalyst highlighted by Guggenheim and one of the biggest clinical uncertainties facing the investment thesis.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
